Lancet Healthy Longevity最新文献

{"title":"Impact of the Sudan conflict on older adults: exacerbating health disparities and threatening longevity","authors":"Ibrahim Nagmeldin Hassan","doi":"10.1016/j.lanhl.2025.100692","DOIUrl":"10.1016/j.lanhl.2025.100692","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 2","pages":"Article 100692"},"PeriodicalIF":13.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The global burden of human metapneumovirus-associated acute respiratory infections in older adults: a systematic review and meta-analysis","authors":"Durga Kulkarni MPH ,&nbsp;Bingbing Cong MMed ,&nbsp;Mamata Jyothish Kumar Ranjini MPH ,&nbsp;Geetika Balchandani IBDP ,&nbsp;Shuting Chen BSMed ,&nbsp;Jingyi Liang MSc ,&nbsp;Lina González Gordon PhD ,&nbsp;Ajoke Sobanjo-ter Meulen MD ,&nbsp;Xin Wang PhD ,&nbsp;Prof You Li PhD ,&nbsp;Richard Osei-Yeboah PhD ,&nbsp;Kate Templeton PhD ,&nbsp;Prof Harish Nair PhD","doi":"10.1016/j.lanhl.2024.100679","DOIUrl":"10.1016/j.lanhl.2024.100679","url":null,"abstract":"<div><h3>Background</h3><div>The human metapneumovirus (hMPV)-associated disease burden in older adults remains under-researched. We aimed to systematically estimate the global burden of hMPV-associated disease in older adults.</div></div><div><h3>Methods</h3><div>We searched MEDLINE, Embase, Global Health, CINAHL, Web of Science, and Global Index Medicus in February, 2023, November, 2023, and October, 2024; and CNKI, Wanfang, and CQVip, in April, 2024, and October, 2024. We included studies conducted over at least 12 consecutive months, reporting on adults aged 60 years or older, and with laboratory-confirmed hMPV infections. Critical appraisal of included studies was conducted using the Joanna Briggs Institute critical appraisal tools. To estimate the hMPV pooled proportions positive in acute respiratory infections (ARIs), random effects meta-analyses were conducted. Using Monte Carlo simulation, we estimated the hMPV-associated hospitalisations globally and separately in high-income countries, low-income and middle-income countries, and the USA in individuals aged 65 years or older in 2019, as most studies reported on this age group. The hMPV-associated ARI incidence in countries other than the USA and in outpatient or community settings in the USA was summarised narratively due to scarcity of data. The review protocol was registered on PROSPERO (CRD42023422325).</div></div><div><h3>Findings</h3><div>46 studies conducted between 2005 and 2023, and reporting on hMPV proportion positive estimates (n=36, with 29 866 laboratory tests), hospitalisation rates in the USA (n=4), and hMPV incidence (n=6) were included. We estimated 473 000 (95% CI 396 000–777 000) hMPV-associated hospitalisations globally, of which 185 000 (105 000–340 000) were in high-income countries (n=6 studies), and 288 000 (193 000–436 000) in low-income and middle-income countries (n=10 studies) in people aged 65 years or older in 2019. In the USA, the pooled hMPV-associated hospitalisation rate was 231 (95% CI 41–421) per 100 000 people in adults aged 65 years or older, representing approximately 122 000 (41 000–398 000) hospital admissions in this population in 2019.</div></div><div><h3>Interpretation</h3><div>hMPV-associated ARIs contribute to a substantial disease and hospitalisation burden in older adults. However, more large-scale surveillance studies and greater investment in research and diagnostic methods are required to develop reliable estimates.</div></div><div><h3>Funding</h3><div>Icosavax, a member of the AstraZeneca group.</div></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 2","pages":"Article 100679"},"PeriodicalIF":13.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical activity and blood-based biomarkers of Alzheimer’s disease: fertile ground for future investigation","authors":"Eddy Roccati","doi":"10.1016/j.lanhl.2025.100691","DOIUrl":"10.1016/j.lanhl.2025.100691","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 2","pages":"Article 100691"},"PeriodicalIF":13.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143520229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thank you to The Lancet Healthy Longevity’s statistical and peer reviewers in 2024","authors":"The Lancet Healthy Longevity Editors","doi":"10.1016/j.lanhl.2025.100688","DOIUrl":"10.1016/j.lanhl.2025.100688","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 2","pages":"Article 100688"},"PeriodicalIF":13.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between moderate-to-vigorous physical activity, p-tau181, and cognition in healthy older adults with memory complaints: a secondary analysis from the MAPT","authors":"Jérémy Raffin PhD ,&nbsp;Prof Kaj Blennow MD PhD ,&nbsp;Prof Yves Rolland MD PhD ,&nbsp;Christelle Cantet MSc ,&nbsp;Sophie Guyonnet PhD ,&nbsp;Prof Bruno Vellas MD PhD ,&nbsp;Prof Philipe de Souto Barreto PhD ,&nbsp;MAPT/IHU HealthAge Open Science Group","doi":"10.1016/j.lanhl.2024.100678","DOIUrl":"10.1016/j.lanhl.2024.100678","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Physical activity provides benefits against cognitive decline but its associations with Alzheimer’s disease pathophysiology are not fully understood. We investigated cross-sectional and longitudinal associations between moderate-to-vigorous physical activity and phosphorylated (p)-tau181 blood concentrations, and the role of p-tau181 in the associations between moderate-to-vigorous physical activity and cognition.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;In this post-hoc secondary analysis, we used data from a multicentre, randomised, placebo-controlled superiority trial (the Multidomain Alzheimer’s Preventive Trial [MAPT]), in which adults aged 70 years and older were recruited from the community in 13 memory centres in France and Monaco. Individuals were eligible if they met at least one of the following criteria: spontaneous memory complaints, low gait speed (≤0·77 m/s), or limitation in at least one instrumental activity of daily living. Exclusion criteria included a dementia diagnosis, a Mini Mental State Examination score below 24, and having limitations in basic activities of daily living. For this secondary analysis, participants from MAPT were included if they had blood p-tau181 concentrations measured at baseline or at 3 years, or both timepoints. Self-reported moderate-to-vigorous physical activity (in metabolic equivalent of task min per week) and a cognitive composite score (calculated by averaging the Z scores of four cognitive tests) were assessed at baseline and at 6 months and at 1, 2, and 3 years. Mixed-effect models were used to examine the cross-sectional and longitudinal associations between moderate-to-vigorous physical activity and p-tau181 concentrations and to explore the mediating and moderating role of p-tau181 concentration on the association between moderate-to-vigorous physical activity and cognition.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;Between May 30, 2008, and Feb 24, 2011, 1679 individuals were enrolled in the MAPT, of whom 558 adults had measurements of p-tau181 concentrations at baseline, 3 years, or both timepoints. Higher levels of moderate-to-vigorous physical activity were associated with slower changes in p-tau181 concentrations over time. Compared with inactive individuals, those with low levels of activity (low moderate-to-vigorous physical activity × time: B = –0·109 [95% CI –0·206 to –0·012; p=0·028]) or high levels of activity (high moderate-to-vigorous physical activity × time: B=–0·114 [95% CI –0·208 to –0·020; p=0·018) had a slower increase in p-tau181 concentrations. We did not identify any association between baseline p-tau181 concentrations and baseline moderate-to-vigorous physical activity levels. The cross-sectional and longitudinal associations between moderate-to-vigorous physical activity and cognition were attenuated with increasing baseline p-tau181 concentrations. Specifically, moderate-to-vigorous physical activity was no longer favourably associated with the ","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 2","pages":"Article 100678"},"PeriodicalIF":13.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143520230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moving beyond the prevalent exposure design for causal inference in dementia research","authors":"Lachlan Cribb MEpi ,&nbsp;Prof Margarita Moreno-Betancur PhD ,&nbsp;Zimu Wu PhD ,&nbsp;Prof Rory Wolfe PhD ,&nbsp;Matthew Pasé PhD ,&nbsp;Prof Joanne Ryan PhD","doi":"10.1016/j.lanhl.2024.100675","DOIUrl":"10.1016/j.lanhl.2024.100675","url":null,"abstract":"<div><div>As randomised trials are not always feasible or practical, observational studies remain crucial for addressing many causal questions in the dementia prevention field. Through a systematic search, we found that 84 (72%) of the 116 latest observational cohort studies that investigated factors hypothesised to reduce the risk of dementia (hearing aids, physical activity, antihypertensives, antidiabetics, and antidepressants) used a prevalent exposure design. The approach of using a prevalent exposure design, which compares dementia risk between individuals with and without prevalent exposure at the start of follow-up, has several limitations, including ill-defined interventions, selection biases, and challenges in adjusting for confounders. This Personal View discusses these limitations using physical activity as a case study and describes an alternative approach based on the target trial framework that can help to overcome such limitations. This approach aligns observational analyses with the design and analysis principles of randomised trials and can, thereby, improve the robustness and relevance of evidence for dementia prevention, which is the ultimate goal.</div></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 2","pages":"Article 100675"},"PeriodicalIF":13.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brothers in arms: RSV and hMPV","authors":"Julian Wei Tze Tang","doi":"10.1016/j.lanhl.2025.100684","DOIUrl":"10.1016/j.lanhl.2025.100684","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 2","pages":"Article 100684"},"PeriodicalIF":13.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-utility of a new psychosocial goal-setting and manualised support intervention for independence in dementia (NIDUS-Family) versus goal setting and routine care: an economic evaluation embedded within a randomised controlled trial","authors":"Abdinasir Isaaq MSc ,&nbsp;Prof Claudia Cooper PhD ,&nbsp;Victoria Vickerstaff PhD ,&nbsp;Prof Julie A Barber PhD ,&nbsp;Prof Kate Walters PhD ,&nbsp;Iain A Lang PhD ,&nbsp;Penny Rapaport Prof ,&nbsp;Vasiliki Orgeta PhD ,&nbsp;Prof Kenneth Rockwood MD ,&nbsp;Prof Laurie T Butler PhD ,&nbsp;Kathryn Lord PhD ,&nbsp;Gill Livingston Prof ,&nbsp;Prof Sube Banerjee MD ,&nbsp;Prof Jill Manthorpe MA ,&nbsp;Prof Helen C Kales MD ,&nbsp;Jessica Budgett MSc ,&nbsp;Prof Rachael Hunter MSc","doi":"10.1016/j.lanhl.2024.100676","DOIUrl":"10.1016/j.lanhl.2024.100676","url":null,"abstract":"<div><h3>Background</h3><div>NIDUS-Family is a psychosocial and behavioural intervention comprising six to eight sessions, delivered by non-clinical facilitators, and tailored to goals set by dyads of people with dementia and their unpaid or family carers. The intervention has been shown to be effective for attainment of personalised client goals. The current study aimed to determine whether the intervention is cost-effective.</div></div><div><h3>Methods</h3><div>In this cost-utility and cost-effectiveness analysis within a two-armed, single-masked, multisite, superiority randomised controlled trial, we recruited 302 people with dementia living in their own homes and their family carers from National Health Service community settings and social and print media across England. Participants were randomly allocated (2:1) to the NIDUS-Family intervention group or control (goal setting and routine care) group. Randomisation was blocked and site-stratified, with allocation by a remote web-based system. We calculated the probability that NIDUS-Family is cost-effective for a client with dementia based on quality-adjusted life-years from a health and social care perspective and from a societal perspective (additionally including family carer time and out-of-pocket costs), at £20 000–30 000 decision thresholds for additional quality-adjusted life-years compared with usual care over 12 months. Analyses were done using the intention-to-treat population. This study is registered with ISRCTN, ISRCTN11425138, and is completed.</div></div><div><h3>Findings</h3><div>Between April 30, 2020, and May 9, 2022, we randomly allocated 204 participants (109 [53%] women and 95 [47%] men) to the intervention group and 98 (60 [61%] women and 38 [39%] men) to the control group. 218 (72%) participants at 6 months and 178 (59%) at 12 months provided cost data. At both a £20 000 and £30 000 decision threshold, there was an 89% probability that NIDUS-Family was cost-effective compared with usual care from a health and social care perspective, and an 87% probability from a societal perspective. Intervention participants accrued on average £8934 (37%) less in costs than control participants (95% CI –£59 460 to £41 592).</div></div><div><h3>Interpretation</h3><div>NIDUS-Family is the first personalised care and support intervention to show both cost-effectiveness from the perspective of the quality of life of people with dementia as well as clinical effectiveness and should therefore be part of routine dementia care.</div></div><div><h3>Funding</h3><div>Alzheimer’s Society.</div></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 2","pages":"Article 100676"},"PeriodicalIF":13.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining obesity to improve ageing","authors":"The Lancet Healthy Longevity","doi":"10.1016/j.lanhl.2025.100696","DOIUrl":"10.1016/j.lanhl.2025.100696","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 2","pages":"Article 100696"},"PeriodicalIF":13.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing NIDUS-Family in practice: a necessary step","authors":"Kate Laver ,&nbsp;Miia Rahja","doi":"10.1016/j.lanhl.2025.100685","DOIUrl":"10.1016/j.lanhl.2025.100685","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 2","pages":"Article 100685"},"PeriodicalIF":13.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}